Running Point Capital Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Running Point Capital Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$13.3K	–	208
2022 Q4	$13.3K	Hold	10,000	–	–	0.01%	189
2022 Q3	$16K	Hold	10,000	–	–	0.01%	188
2022 Q2	$15K	Hold	10,000	–	–	0.01%	196
2022 Q1	$26K	Buy	+10,000	New	+$24.4K	0.02%	177

Other funds holding XERS

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Running Point Capital Advisors's XERS Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Xeris Biopharma Holdings (XERS) in Q1 2023, closing a stake of 10,000 shares — an estimated $13.3K sold.

Running Point Capital Advisors first reported a position in XERS in Q1 2022 and held it in 4 quarters. The position peaked at $26K in Q1 2022. 92 funds tracked by Wall St. Rank hold XERS as of Q1 2023.

Running Point Capital Advisors reported no remaining Xeris Biopharma Holdings position as of Q1 2023 after selling out during the quarter.
Running Point Capital Advisors sold 10,000 Xeris Biopharma Holdings shares in Q1 2023, an estimated $13.3K.
Running Point Capital Advisors first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 4 quarters.
Running Point Capital Advisors's Xeris Biopharma Holdings position peaked at $26K in Q1 2022.
92 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.